Charles Waterfield
Director of Respiratory, Inflammation, Autoimmunit
Diabetes and endocrinology
AstraZeneca
Australia
Biography
Charles Waterfield is the Business Unit Director for Respiratory, Inflammation, Autoimmunity (RIA) and Established Brands at AstraZeneca Australia and New Zealand. In this role, he is responsible for the products in this portfolio and for the sales and marketing teams working with these therapies. Charles has been a member of the senior management team since 2008 and prior to his current role was Director of Market Access, External Affairs and Commercial Excellence.
Research Interest
Charles has also held a number of sales and marketing roles within the organisation including Business Unit Head of Neuroscience and Marketing Manager of Gastrointestinal Products. During that time, Charles successfully launched Seroquel XR (quetiapine fumarate) and launched and managed the growth of Nexium (esomeprazole magnesium trihydrate), which was awarded the International Sales and Marketing Organisation (ISMO) market share performance award for two consecutive years. Prior to joining AstraZeneca, Charles was a partner in a business that operated a chain of pharmacies and medical centres in Johannesburg, South Africa. Qualifications Charles has a BPharm from the University of the Witwatersrand, Johannesburg, South Africa, and a Masters in Business Administration from Edinburgh Business School, Heriot Watt University, Scotland.
